Research-use information only. This article summarises published laboratory and pre-clinical findings for CJC-1295 and Ipamorelin. Neither peptide is a licensed medicine in the UK, and neither is approved for human consumption. Nothing here is medical, dosing or therapeutic advice.
Few peptide pairings appear in the research literature as often as CJC-1295 combined with Ipamorelin. The logic is straightforward once you look at where each molecule acts: one lifts the baseline signal for growth-hormone release, the other adds a sharp, clean pulse on top. Studied together, they are used as a model for how the pituitary can be prompted along two complementary pathways at once. This guide walks through the mechanism, what the published work actually shows, how dosing is described in research protocols, and the purity questions that matter most for anyone sourcing these compounds for laboratory work in the UK.
What CJC-1295 and Ipamorelin are
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that tells the anterior pituitary to secrete growth hormone. Structurally it is a modified GHRH(1–29) fragment, engineered for greater metabolic stability than native GHRH. It exists in two forms researchers should not confuse: with DAC (Drug Affinity Complex), which binds albumin and extends the half-life to several days, and without DAC (often labelled Mod-GRF 1-29), which clears quickly and produces a short, physiological rise.
Ipamorelin is a selective pentapeptide growth-hormone secretagogue. It acts on the ghrelin receptor (GHS-R1a) rather than the GHRH receptor, and is prized in the literature for its selectivity: unlike earlier secretagogues such as GHRP-6, it drives growth-hormone release with little effect on cortisol or prolactin in reported models. In practical terms, the two peptides pull the same lever from two different sides.
Why they are studied together: the “pulse and sustain” model
Native growth hormone is not released in a steady stream; it comes in pulses, largely overnight. CJC-1295 without DAC raises the GHRH signal so the pituitary is primed, while Ipamorelin triggers a discrete secretory burst through the ghrelin pathway. Because the two receptors sit on different signalling cascades, researchers observe an additive — and in some models synergistic — release compared with either peptide alone. This is the mechanistic reason the pairing dominates the literature on growth-hormone secretagogue research, and why the two are almost always discussed as a blend rather than in isolation.
It is worth being precise about what “benefit” means here. Most of the widely cited outcomes — changes in lean-tissue markers, fat oxidation, recovery and sleep architecture — come from animal models, small early-phase human studies, or downstream reasoning from raised IGF-1. They describe biological signals under investigation, not established clinical effects.
How dosing is described in the research literature
In published and protocol literature, the CJC-1295 (no DAC) and Ipamorelin blend is typically described in microgram quantities, most often around a 1:1 to 2:1 ratio, reconstituted in bacteriostatic water and studied on a timed schedule that mirrors the body’s own pulsatile release — commonly modelled before rest, when endogenous growth-hormone output is naturally highest. The DAC version is described far less frequently on a daily cadence because its extended half-life changes the exposure profile entirely.
These figures describe how the compounds appear in laboratory documentation; they are not a protocol for use in humans. For the practical mechanics of preparing lyophilised material, our UK laboratory guide to reconstituting peptides covers dilution maths, storage and handling in detail.
Side-effect and safety signals reported in research
The most consistently reported observations across secretagogue research are transient: injection-site reactions, a brief flush or head-rush, water retention, and tingling in the extremities linked to fluid shifts. Because the pairing raises IGF-1, the literature also flags the theoretical relevance of glucose handling, which is why insulin sensitivity is a standard monitored parameter in study designs. Ipamorelin’s selectivity is the reason it is favoured over older secretagogues — the cortisol and prolactin elevations seen with less selective compounds are largely absent in reported data. None of this establishes a human safety profile; it maps what researchers watch for.
The UK regulatory picture
This is the part most guides gloss over. In the UK, CJC-1295 and Ipamorelin are not licensed medicines. Supplying them for human use without MHRA authorisation falls under the Human Medicines Regulations 2012. Legitimate supply in this market is therefore for laboratory and research purposes only, and reputable UK suppliers label them accordingly. For a fuller treatment of how UK legality and sourcing intersect, see our guide on buying research peptides in the UK.
Purity and sourcing: what actually matters
For a blend, purity questions double. You want third-party HPLC verification of identity and purity for both peptides, mass-spectrometry confirmation of molecular weight, and a batch-specific Certificate of Analysis rather than a generic template. Reconstitution introduces its own variables — endotoxin load and correct lyophilisation matter as much as the headline purity percentage. A supplier that publishes COAs per batch is doing the one thing that separates research-grade material from the grey market.
Frequently asked questions
What does CJC-1295 and Ipamorelin do?
Studied together, they stimulate the pituitary to release growth hormone through two complementary pathways — CJC-1295 raises the GHRH signal, Ipamorelin adds a ghrelin-receptor pulse. Reported research interest centres on body composition, recovery and sleep markers, though most evidence is pre-clinical.
What are the reported side effects of CJC-1295 and Ipamorelin?
Research most often reports injection-site reactions, transient flushing, water retention and tingling in the hands or feet. Because IGF-1 rises, glucose handling is a routinely monitored parameter in study designs.
How long does it take to see results from CJC-1295 and Ipamorelin?
Growth-hormone release is acute — measurable within an hour of administration in pharmacokinetic studies. Downstream markers such as IGF-1 shift over weeks in the reported literature. Timelines outside controlled study conditions are not established.
Is Ipamorelin legal in the UK?
Ipamorelin is not a licensed medicine in the UK. Supplying it for human use without MHRA authorisation is unlawful under the Human Medicines Regulations 2012; supply for laboratory research is a separate, lawful category when correctly labelled.
What is the difference between CJC-1295 with DAC and without DAC?
With DAC, CJC-1295 binds albumin and stays active for days, producing a sustained elevation. Without DAC (Mod-GRF 1-29), it clears in minutes to hours, giving a short physiological pulse that pairs naturally with Ipamorelin. See our dedicated comparison for the full breakdown.
Related research reading: CJC-1295 UK complete research guide · What is Ipamorelin and how does it work · CJC-1295 with DAC vs without DAC.
